Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc. is poised for a positive trajectory, driven by increasing confidence in the efficacy of its clinical-stage gene therapy candidates TN-201 and TN-401, with success probabilities adjusted upward to 30% and 15%, respectively. The presentation of promising preclinical data for TN-301, highlighting significant improvements in muscle strength and reduced biomarkers of muscle damage, further bolsters the company's potential in treating rare genetic disorders. Additionally, encouraging safety profiles and clinically meaningful improvements in patients receiving TN-401 indicate a strong foundation for future developments and regulatory alignments anticipated in 2026.

Bears say

The analysis highlights significant concerns regarding Tenaya Therapeutics Inc., primarily due to the potential delays in transitioning preclinical assets to the clinical stage, which could adversely affect market sentiment and prompt downward revisions to financial estimates. Additionally, the company's ability to scale manufacturing capacity poses a risk to meeting forecasts, further complicating its financial outlook. Furthermore, emerging safety signals related to immune reactions during clinical trials could negatively impact both investor confidence and the company's valuation.

Tenaya Therapeutic (TNYA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.